Held by 4 specialist biotech funds
High Convergence# Signal Note: Perceptive Advisors Initiates PALI Position Edelman's $28.3M entry into Palisade Bio signals conviction in the company's clinical pipeline, likely driven by PALI-2501 (a dual GLP-1/GCG receptor agonist for obesity/metabolic disease) advancing toward pivotal studies in a competitive but high-value space.
AI analyst context — unlock full analysis
**Signal Note: Commodore Capital Initiates $26.9M Position in Palisade Bio** Pellini's entry into PALI is noteworthy given his precision oncology pedigree at Foundation Medicine; Palisade's lead program PALI-1 (a TLR7/8 agonist) is in Phase 2 for checkpoint inhibitor-resistant melanoma and other solid tumors, with potential data readouts expected in 2025. The ~11.4M share position (~4-5% stake) suggests conviction in either near-term clinical validation or M&A attractiveness in the immunotherapy space, particularly as combination IO approaches remain heavily capitalized.
+ 2 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial